

Patrick Loose, Chief
HIV, STD & Hepatitis Branch
March 15, 2018






MISSION

Improve health outcomes in communities disproportionately impacted by HIV and STDs





Collect, study and publish data

Diagnose and investigate priority diseases

Educate residents about sexual health

Work in partnership with communities

Provide policy recommendations

Connect people to care and treatment services

Provide or purchase services

Develop workforce capacity & competency

Ensure quality

Support continued research




STD PRIORITIES

Prevent congenital syphilis cases Investigate and intervene in infectious syphilis cases Investigate and intervene in syphilis and gonorrhea cases that can lead to HIV transmission Monitor GC resistance **PrEP** Build capacity of youth-serving organizations to support sexual health


STDs Reported Among San Diego County Residents, 1997 – 2016






GONORRHEA CALIFORNIA INCIDENCE RATES, 1913–2016






PRIMARY & SECONDARY SYPHILIS, CA & UNITED STATES INCIDENCE RATES, 1941–2016








Note: Rate categories are dfiferent from the last iteration of this report

Source: County of San Diego, Health and Human Services Agency, HSHB (HIV, STD, Hepatitis Branch), CalREDIE Database

Map Date: June 10, 2016 Contact: Lawrence Wang





Note: Rate categories are different from the last iteration of this report


Source: County of San Diego, Health and Human Services Agency, HSHB (HIV, STD, Hepatitis Branch), CalREDIE Database

Map Date: June 10, 2016 Contact: Lawrence Wang






PRIMARY & SECONDARY SYPHILIS, 1988 – 2015









HIV CO-INFECTION AMONG MSM CASES



Rates of Primary and Secondary Syphilis among Men who have sex with Men (MSM), men who have sex with women only (MSW), and women. United States, 1963-2013



Estimated using modified Heffelfinger M:F rate ratio of 1.1236, assuming no MSM had syphilis in 1994, and estimating 3.9% of men are MSM



Note: Rate categories are dfiferent from the last iteration of this report


Source: County of San Diego, Health and Human Services Agency, HSHB (HIV, STD, Hepatitis Branch), CalREDIE Database

Map Date: June 10, 2016 Contact: Lawrence Wang




Chlamydia, Gonorrhea, and Early Syphilis Ranking of County Incidence Rates, California, 2015

(with 95% Confidence Intervals*)



Confidence intervals were calculated using Poisson exact method; not shown for counties with zero cases


Female Early Syphilis* and Congenital Syphilis Cases California, 2009–2015






^{*} Includes primary, secondary, and early latent syphilis.

Congenital Syphilis Number of Cases by County, California, 2015





Congenital Syphilis Incidence Rates by County, California, 2015






STD PREVENTION

Chlamydia Screening Project STD Community Intervention Project

Don't Think, Know










GONORRHEA SURVEILLANCE

California Gonorrhea Surveillance System

Gonococcal Isolate Surveillance Project

Gonococcal Isolate Surveillance Project (GISP), Percent of *Neisseria Gonorrhoeae* Isolates with CDC "Alert" Values for Selected Cephalosporins in California GISP STD Clinic Sites, 1992–April 2016




* Cefixime susceptibility was not run in 2007-2008.

Note: "Alert" values are set by CDC as markers to look at possible decreased susceptibility. Cefixime alerts have MICs \geq 0.25 µg/mL. Ceftriaxone alerts have MICs \geq 0.125 µg/mL. 2015-2016 data are provisional as of 6/20/2016.

STD Clinic Sites: Long Beach (ended participation in 2007), Los Angeles (added in 2003), Orange,

San Diego, San Francisco

Gonococcal Isolate Surveillance Project (GISP), Percent of *Neisseria Gonorrhoeae* Isolates with CDC "Alert" Values for Azithromycin in California GISP STD Clinic Sites, 1992–April 2016



Note: "Alert" values are set by CDC as markers to look at possible decreased susceptibility. Azithromycin alerts have MICs ≥ 2.0 µg/mL. No data before 1992. 2015-2016 data are provisional as of 6/20/2016.

STD Clinic Sites: Long Beach (ended participation in 2007), Los Angeles (added in 2003), Orange, San Diego, San Francisco







County of San Diego Monthly STD Report

Volume 8. Issue 6: Data Through Feb 2016: Report Released June 10, 2016.




	Feb	2015 Previous 12- Month Period"	Feb	2016 Previous 12- Month Period
Chlamydia	1267	15481	1482	18009
Female age 18-25	538	6270	607	7184
Female age ≤ 17	62	665	63	816
Male rectal chlamydia	51	509	42	617
Gonomhea	293	3382	389	3898
Female age 18-25	43	499	55	511
Female age ≤ 17	3	67	9	72
Male rectal gonorrhea	54	452	56	531
Early Syphilis (adult total)	61	706	77	849
Primary	10	124	13	186
Secondary	27	260	27	318
Early latent	24	322	37	345
Congenital syphilis	0	4	0	10
HIV Infection [†]				
HIV (not AIDS)	37	441	43	476
AIDS	28	239	22	212


⁺ New infections are reported either as HIV, or if an individual was also diagnosed with AIDS within one month, as AIDS.

Table 2. Selected STD Cases and Annualized Rates per 100,000 Population for San Diego County by Age and Race/Ethnicity, Year to Date. All Races* Asian/PI Black Hispanic cases rate cases rate cases rate cases rate cases rate All ages Chlamydia 3248 627.4 20 32.2 52 225.7 215 119.6 130 51.5 785 151.6 9 14.5 62 269.2 160 89.0 149 59.0 149 28.8 9 14.5 10 43.4 54 30.0 60 23.7 Under 20 vrs Chlamydia 4 25.8 9 149.4 35 56.8 11 22.1 2 13.4 7 116.2 19 30.0

3 47

6 45





Note: All data are provisional. Case counts are based on the earliest of date of diagnosis, date of specimen collection, and treatment date. Totals for past months might change because of delays in reporting from labs and providers.

Editorial Note: Changes in Pelvic Inflammatory Disease Reporting Requirements

The California Department of Public Health, in consultation with the California Conference of Local Health Officers, recently updated Title 17 sections 2500, 2502 and 2505 of the California Code of Regulations. Effective June 3, 2016, CDPH no longer requires that pelvic inflammatory disease (PID) be reported to the local health department. Therefore, cases of PID, other than those caused by a reportable sexually transmitted pathogen (i.e., Neisseria gonorrhoeae or Chlamydia trachomatis), do not require a Confidential Morbidity Report to the health department.

PID comprises a spectrum of inflammatory disorders of the upper female genital tract and may include endometritis, salpingitis, tubo-ovarian abscess, and/or pelvic peritonitis. A significant but declining proportion of PID cases are due to N. gonorrhoeae or C. trachomatis. Anaerobic bacteria, Gardnerella vaginalis, Haemophilus influenzae, enteric Gram-negative rods, Streptococcus agalactiae, cytomegalovirus, Mycoplasma hominis, Ureaplasma urealyticum, and Mycoplasma genitalium also have been implicated in this condition. Most cases of PID are diagnosed based on the presence of pelvic or lower abdominal pain plus lack of any other cause of the pain plus one of the following minimum clinical criteria: cervical motion tenderness or uterine tendemess or adnexal tenderness [1].

Recommended treatment regimens reflect the polymicrobial nature of many cases of PID. Women with mild to moderate disease may be treated with intramuscular/oral antibiotic regimens, while women with severe illness, signs/symptoms indicative of a surgical emergency, tubo-ovarian abscess, pregnancy, or inability to follow or tolerate an outpatient regimen should be hospitalized and receive parenteral therapy. These recommendations are outlined in the Centers for Disease Control and Prevention (CDC) 2015 STD Treatment Guidelines

Providers should indicate the presence of PID in case reports for N. gonorrhoeae and C. trachomatis by checking "Gonococcal PID" and/or "Chlamydial PID," in addition to providing other required information about these infections (i.e., specimen sources, presence of symptoms, treatment,

A current list of reportable communicable diseases under Title 17 Section 2500 can be found here. For questions regarding PID diagnosis, management, and/or reporting requirements please page (877) 217-1816. For other Title 17 changes that may be relevant to your practice, please see the attached letter from CDPH.

County of San Diego STD Clinics: www.STDSanDiego.org Phone: (619) 692-8550 Fax: (619) 692-8543 STD Clinical Consultation Pager: (877) 217-1816 (8am-5pm, M-F)



^{2 13.4}







To: CAHAN San Diego Participants CAHANSANDIEGOMASTHEAD-8-25-09

Date: June 19, 2015

Invasive Meningococcal Disease in Men Who Have Sex with Men

This health advisory informs local healthcare professionals of cases of invasive meningococcal disease (IMD) in men who have sex with men (MSM) in several U.S. cities and provides vaccine recommendations for at-risk individuals who plan travel to these locations. At this time, there have been no reported IMD cases in MSM in San Diego County.



Date: May 10, 2016

To: CAHAN San Diego Participants

From: Public Health Services, HIV, STD and Hepatitis Services Branch

Limited Availability of Long-Acting Bicillin

This health advisory notifies CAHAN participants that there is a national shortage of the long-acting form of benzathine penicillin G that is recommended for treatment of most stages of syphilis and <u>all</u> pregnant women with syphilis (i.e., Bicillin LA) and requests local providers to prioritize the use of Bicillin LA for pregnant women who are infected with or exposed to syphilis.





STD CLINICAL SERVICES

Rosecrans STD Clinic

Central Regional Public Health Center

North Coastal Regional Public Health Center

South Regional Public Health Center



STD & HIV FIELD SERVICES

Syphilis Investigation

HIV Results Disclosure

HIV/STD Integration (Rectal GC)

Partner Services (HIV, Syphilis, some GC)

Surveillance-Based HIV Partner Services

Data to Care



OPPORTUNITIES AND FUTURE DIRECTIONS

Increase epidemiology workforce to collect and analyze data

Integrate HIV and STD epidemiology and surveillance

Expand workforce

Invest in workforce competency development

Develop medical systems' capacity to prevent congenital syphilis

Advocate for increased funding and resources for STDs

Advocate for building capacity of medical systems and youth-serving organizations to address sexual health

Advocate for research



